Illumina Company Profile

Aggregated data from the web about Illumina

Company Name	Illumina
Website	https://www.illumina.com
Snippet	The Illumina COVIDSeq Test is a Next-Generation Sequencing (NGS) in vitro diagnostic test on the Illumina NovaSeq 6000 Sequencing System, NextSeq 2000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument intended for the qualitative detection of SARS-CoV-2 RNA from nasopharyngeal (NP ...
Type	Public
Founded	1998
Founder	David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, Mark Chee
Revenue	US$3.33 billion (2018)
Website	www.illumina.com
Industry	Biotechnology
Products	NovaSeq 6000, HiSeq X, HiSeq 4000, MiSeq, MiSeqDx, MiniSeq, iSeq 100, NextSeq 550, NextSeq 550Dx, iScan
Traded as	NASDAQ: ILMNNASDAQ-100 ComponentS&P 500 Component
Key people	Francis deSouza (President & CEO), Jay Flatley (Executive Chairman), Sam Samad (CFO)
Net income	US$826 million (2018)
Headquarters	San Diego, California, U.S.
Operating income	US$883 million (2018)
Number of employees	~7,300

Illumina is part of the United States company list

Illumina is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.